Celldex Therapeutics (NASDAQ:CLDX) Shares Up 4.9% – Should You Buy?

Celldex Therapeutics, Inc. (NASDAQ:CLDX)’s stock price traded up 4.9% on Tuesday . The stock traded as high as $24.59 and last traded at $24.46. 187,152 shares were traded during trading, a decline of 79% from the average session volume of 872,933 shares. The stock had previously closed at $23.31.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on CLDX shares. Wolfe Research lowered Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a report on Friday, September 27th. The Goldman Sachs Group assumed coverage on shares of Celldex Therapeutics in a research note on Monday, September 30th. They issued a “neutral” rating and a $45.00 price objective on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $67.00 target price on shares of Celldex Therapeutics in a research note on Monday, September 16th. Wells Fargo & Company upgraded shares of Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday, September 26th. Finally, HC Wainwright reiterated a “buy” rating and issued a $80.00 target price on shares of Celldex Therapeutics in a research note on Wednesday. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Celldex Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $62.25.

Celldex Therapeutics Stock Performance

The business has a fifty day simple moving average of $31.17 and a two-hundred day simple moving average of $35.15.

Insider Buying and Selling

In other news, CEO Anthony S. Marucci bought 11,500 shares of the stock in a transaction dated Monday, November 11th. The shares were acquired at an average price of $26.82 per share, with a total value of $308,430.00. Following the acquisition, the chief executive officer now owns 40,284 shares in the company, valued at $1,080,416.88. This trade represents a 39.95 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 3.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Celldex Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. KBC Group NV boosted its holdings in shares of Celldex Therapeutics by 31.2% in the 3rd quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock worth $71,000 after acquiring an additional 495 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in Celldex Therapeutics in the second quarter worth $76,000. CANADA LIFE ASSURANCE Co boosted its stake in Celldex Therapeutics by 26.4% in the first quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock worth $192,000 after purchasing an additional 955 shares in the last quarter. Ameritas Investment Partners Inc. grew its holdings in shares of Celldex Therapeutics by 34.3% during the first quarter. Ameritas Investment Partners Inc. now owns 6,198 shares of the biopharmaceutical company’s stock worth $260,000 after purchasing an additional 1,582 shares during the last quarter. Finally, Quest Partners LLC increased its stake in shares of Celldex Therapeutics by 1,364.9% in the second quarter. Quest Partners LLC now owns 7,383 shares of the biopharmaceutical company’s stock valued at $273,000 after buying an additional 6,879 shares in the last quarter.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.